CAJ | 학술논문

内分泌治疗是激素受体阳性乳腺癌的重要系统治疗手段,但原发性与继发性耐药是当前内分泌治疗的难题.雌激素受体通路与其他受体通路的交互效应是耐药机制之一.抑制磷脂酰肌醇3-激酶(PI3K)-蛋白激酶B(Akt)-哺乳动物雷帕霉素靶蛋白(mTOR)、表皮生长因子受体(EGFR)等分子通路逆转内分泌耐药的临床研究已取得一定的成果.
내분비치료시격소수체양성유선암적중요계통치료수단,단원발성여계발성내약시당전내분비치료적난제.자격소수체통로여기타수체통로적교호효응시내약궤제지일.억제린지선기순3-격매(PI3K)-단백격매B(Akt)-포유동물뢰파매소파단백(mTOR)、표피생장인자수체(EGFR)등분자통로역전내분비내약적림상연구이취득일정적성과.
Endocrine therapy is the most important systemic therapy for hormone receptor positive breast cancer.However,intrinsic or acquired resistance to endocrine therapy is a challenge currently.Crosstalk between estrogen receptor pathway and other pathway is considered to be one of the underlying mechanisms.Progress has been made in reversing resistance by blocking signaling through pathways such as the phosphoinositide 3-kinasesprotein kinase B-mammalian target of rapamycin and epidermal growth factor receptor pathway.